Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Brentuximab Vedotin

Department of Health written question – answered on 15th February 2017.

Alert me about debates like this

Photo of Henry Smith Henry Smith Conservative, Crawley

To ask the Secretary of State for Health, what steps his Department is taking to ensure relapsed and refractory Hodgkin lymphoma patients continue to have access to brentuximab vedotin.

Photo of Nicola Blackwood Nicola Blackwood The Parliamentary Under-Secretary of State for Health

Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides independent, evidence-based guidance for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE is appraising Brentuximab for this indication and recently consulted stakeholders on its draft recommendations. Brentuximab is currently available to NHS patients with relapsed and refractory Hodgkin lymphoma through the Cancer Drugs Fund.

Does this answer the above question?

Yes0 people think so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.